Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...
Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...
Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...
Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...
In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...
Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...
Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...
Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...
Incog BioPharma, a sterile injectables CDMO, plans to shell out around $200 million to boost production capacity at its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results